Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 5 institutions in 1 country.
Oyomoare L Osazuwa-PetersDepartment of Population Health Sciences, Duke University School of Medicine, Durham, NC 27701, USA.ORCID 0000-0002-6601-657X
April DeveauxDepartment of Population Health Sciences, Duke University School of Medicine, Durham, NC 27701, USA.
Michael J MuehlbauerDuke University School of Medicine, Duke Molecular Physiology Institute, Durham, NC 27701, USA.
Olga IlkayevaDuke University School of Medicine, Duke Molecular Physiology Institute, Durham, NC 27701, USA.ORCID 0000-0002-9779-0883
James R BainDuke University School of Medicine, Duke Molecular Physiology Institute, Durham, NC 27701, USA.ORCID 0000-0002-8917-9187
Temitope KekuDivision of Gastroenterology and Hepatology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Andrew BerchuckDuke Division of Gynecologic Oncology, Duke University School of Medicine, Durham, NC 27710, USA.
Bin HuangKentucky Cancer Registry, University of Kentucky, Lexington, KY 40506, USA.
Kevin WardGeorgia Cancer Registry, Emory University, Atlanta, GA 30322, USA.
Margaret Gates KuliszewskiNew York State Cancer Registry, New York State Department of Health, Albany, NY 12204, USA.
Tomi AkinyemijuDepartment of Population Health Sciences, Duke University School of Medicine, Durham, NC 27701, USA.ORCID 0000-0002-1412-3234
Duke University · USEmory University · USNew York State Department of Health · USUniversity of Kentucky · USUniversity of North Carolina at Chapel Hill · US
Funding
University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Jennifer F Rogers · 2013 to 2026
$38.3M
Resource Core 3 - Metabolomics CoreP30AG028716 · NIA · DUKE UNIVERSITY · PI CATHLEEN S COLON-EMERIC, Susan Nicole Hastings · 2006 to 2026
$24.6M
Pilot & Feasibility ProgramP30DK124723 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI P Darrell Neufer · 2020 to 2026
$11.0M
Stress-related inflammation and racial disparities in ovarian cancerR37CA233777 · NCI · DUKE UNIVERSITY · PI AKINYEMIJU, TOMI F · 2019 to 2025
$4.2M
Predicting Newborn and Childhood Adiposity: An Integrated Omics ApproachR01DK117491 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LOWE, WILLIAM L, SCHOLTENS, DENISE M · 2018 to 2022
$2.8M
Biomarkers of Dietary Intake and Exposure Data Coordinating CenterU24DK129557 · NIDDK · DUKE UNIVERSITY · PI CHAKRABORTY, HRISHIKESH · 2021 to 2025
$2.6M
SCIENTIFIC, OPERATIONS AND ADMINISTRATIVE RESOURCES (SOAR) TO THE NIH75N95021D00011 · NIDA · GAP SOLUTIONS, INC. · PI RUPPERT, STEVEN · 2025 to 2025
The vaginal microbiome differs by race and contributes to inflammation by directly producing or consuming metabolites or by indirectly inducing host immune response, but its potential contributions to ovarian cancer (OC) disparities remain unclear. In this exploratory cross-sectional study, we examine whether vaginal fluid metabolites differ by race among patients with OC, if they are associated with systemic inflammation, and if such associations differ by race. Study participants were recruited from the Ovarian Cancer Epidemiology, Healthcare Access, and Disparities Study between March 2021 and September 2022. Our study included 36 study participants with ovarian cancer who provided biospecimens; 20 randomly selected White patients and all 16 eligible Black patients, aged 50-70 years. Acylcarnitines (n = 45 species), sphingomyelins (n = 34), and ceramides (n = 21) were assayed on cervicovaginal fluid, while four cytokines (IL-1β, IL-10, TNF-α, and IL-6) were assayed on saliva. Seven metabolites showed >2-fold differences, two showed significant differences using the Wilcoxon rank-sum test (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Racial Differences in Vaginal Fluid Metabolites and Association with Systemic Inflammation Markers among Ovarian Cancer Patients: A Pilot Study. · full record | OpenQuestion